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Celiac disease (CD) is an immune-mediated enteropathy, triggered by dietary wheat gluten and similar proteins of barley and rye
in genetically susceptible individuals. The etiology of this disorder is complex, involving both environmental and genetic factors.
The major genetic risk factor for CD is represented by HLA-DQ genes, which account for approximately 40% of the genetic risk;
however, only a small percentage of carriers develop the disease. Gluten is the main environmental factor responsible for the
signs and symptoms of the disease, but exposure to gluten does not fully explain the manifestation of CD. Epidemiological and
clinical data suggest that environmental factors other than gluten might play a role in disease development, including early feeding
practices (e.g., breast milk versus formula and duration of breastfeeding), infections, and alterations in the intestinal microbiota
composition. Herein, we review what is known about the influence of dietary factors, exposure to infectious agents, and intestinal
microbiota composition, particularly in early life, on the risk of developing CD, as well as the possible dietary strategies to induce
or increase gluten tolerance.
1. Introduction
CD is an immune-based enteropathy triggered by dietary
wheat gluten and similar proteins in barley and rye in genet-
ically susceptible individuals. The histological features of
CD are villous atrophy, crypt cell hyperplasia, and increased
number of intraepithelial cells. It is generally accepted that
CD is a T-cell mediated disease, in which gliadin-derived
peptides activate lamina propria, infiltrating T lymphocytes.
This leads to the release of proinflammatory cytokines, such
as IFN-γ and IL-15, which are responsible for the activation
of the cytotoxicity of intraepithelial lymphocytes that leads
to a profound tissue remodeling [1, 2].
This is a complex disorder, with environmental and
genetic factors contributing to its etiology. The main genetic
influence on CD is the HLA locus [3], specifically MHC
class II genes that encode HLA-DQ2 (HLA-DQ2.5 and HLA-
DQ2.2) and HLA-DQ8 heterodimers. The strongest associa-
tion is with HLA-DQ2.5 heterodimer. The risk heterodimer
HLA-DQ2.5 can be encoded in cis, when both DQA1∗0501
andDQB1∗0201 alleles are located on the same haplotype, or
in trans, when these two molecules are located on diﬀerent
haplotypes [4]. HLA-DQ genes account for approximately
40% of the genetic risk. Around 90–95% of CD patients
express HLA-DQ2 heterodimer while the remaining 5–10%
patients express the HLA-DQ8 heterodimer [2]. However, it
is still unknown why only a subset of individuals expressing
HLA-DQ2 and HLA-DQ8 heterodimers develop CD, and
why some do so very early in infancy after their first exposure
to gluten, and others in adulthood [2, 5]. Thus, HLA-DQ2
and HLA-DQ8 heterodimers underlie the disorder but are
not suﬃcient alone, thus other genetic and environmental
factors must be involved in CD onset [5].
To date, gluten is the only known environmental factor
to play a direct causal role in CD, and the only treatment
for CD is a gluten-free diet (GFD). Wheat-gluten proteins
include gliadins and glutenins. The closely related proteins
in barley and rye that activate CD are hordeins and secalins,
respectively. The gliadins are subdivided into α/β, γ, and ω-
gliadins, while the glutenins consist of low molecular weight
2 Clinical and Developmental Immunology
(LMW) and high molecular weight (HMW) glutenins.
Gluten has high concentrations of glutamine and proline
residues (35 and 15% of the total amino acid content)
[6]. High proline content renders these proteins resistant
to complete proteolytic digestion by gastric, pancreatic, and
brush border enzymes in the human intestine, since these
enzymes are deficient in prolylendopeptidase activity [7, 8],
making it possible for large immunogenic gluten peptides
to accumulate and reach the mucosal surface [8, 9]. While
gluten is the main environmental factor responsible for the
signs and symptoms of CD, other environmental elements
might play a role in disease onset, either on their own or by
interaction with gluten exposure.
1.1. Prevalence and Epidemiology. The first publication to
demonstrate the true magnitude of CD was published by
Catassi et al. in 1996, reporting a CD prevalence of 1 : 184
in an Italian scholar population and a ratio of known to
undiagnosed CD cases of 1 in 7 [10]. Although screening
studies predict CD to aﬀect approximately 1% of the US
population, including both children and adults, only 10–
15% of these individuals have been diagnosed and treated
[11]. An international serological screening study revealed
diﬀerences in populations across Europe with high values in
Finland (2.4%) and low values in Germany (0.3%), while
prevalence recorded in Italy was 0.7% [12]. An analysis by
Abadie et al. [4] showed there are no significant correlations
between CD prevalence worldwide and wheat consumption,
or between the sum of DR3-DQ2 and DR4-DQ8 frequencies,
or the product of both factors. This would suggest that
other environmental and genetic factors must contribute
to the development or pathogenesis of CD. Due to the
heterogeneity of CD manifestations, epidemiologists refer
to the clinical and pathological spectrum of the disease as
an iceberg, including active, silent, latent, and potential CD
[4, 10, 13].
1.2. Immunopathology of Celiac Disease
1.2.1. Adaptive Immune Response: Gluten and HLA-DQ
Molecules. It is well known that gluten specific CD4+ T
cells can be isolated from CD patients but not from healthy
individuals [14]. In CD patients, gluten-derived peptides
are recognized by HLA-DQ2 or HLA-DQ8 heterodimers
of antigen-presenting cells, which trigger a CD4+ T cell
response. These two HLA-DQ molecules have preference for
negatively charged peptides. Although native gluten peptides
lack negative residues, the tissue transglutaminase 2 (TG2)
can convert noncharged glutamine into negatively charged
glutamic acid, a process called deamidation. Deamidated
gluten peptides are presented to CD4+ T cells with subse-
quent release of proinflammatory cytokines, such as IFN-
γ that enhances activation of cytotoxic CD8 intraepithelial
lymphocytes, contributing to a profound tissue remodeling.
TG2 is mostly retained intracellularly in an inactive
form and is activated upon its release during tissue damage;
however, the question of how TG2 is converted to its active
form is still unclear. Tjon et al. [15] suggest that CD4+ T cells
could respond against native gluten peptides representing
the first breach in oral tolerance to gluten. Activated gluten-
specific CD4+ T cells can also stimulate B-cell production
of antigluten, as well as anti-TG2 antibodies [16]. In 1970,
Shiner and Ballard [17] were the first to report IgA deposit
in the basement membrane of surface epithelial cells, in
crypt epithelium, around the subepithelial fibroblast and in
the walls of blood vessels in the intestinal mucosa of celiac
patients, later corroborated by other studies [18, 19]. IgA
deposits have also been found in skin and brain promoting
dermatitis herpetiformis [20] and gluten ataxia, respectively
[21]. However, whether IgA antibodies against either gluten
or the autoantigen TG2 are byproducts of the intestinal
adaptive immune response or whether they play a direct role
in CD pathogenesis remains unclear [2].
Recently, Matysiak-Budnik et al. [22] hypothesized a
transport function for antigliadin IgA antibodies. They pro-
posed that gluten peptides may be complexed to intraluminal
secretory IgA, bound to an IgA receptor and transported,
protected from lysosomal degradation by a specific tran-
scytosis pathway. The transcytosis of IgA in CD seems to
involve the transferrin receptor CD71, since in active CD,
CD71 expression is increased and CD71 is found at the
apical enterocyte membrane where it colocalizes with IgA.
By contrast, in the normal intestine and in patients on a
gluten-free diet, CD71 is only expressed on the basolateral
enterocyte membrane.
1.2.2. Intraepithelial Lymphocytes: Between Adaptive and
Innate Responses. Most IELs are CD8+ TCRαβ+ T cells (75%
CD8+ TCRαβ and 15% TCRγδ+ T cells) [2]. In active
CD the number of IELs (CD8+ TCRαβ+ and TCRγδ+ T
cells) is increased. In active CD, IELs express high levels
of activating receptors like CD94/NKG2C and NKG2D [23]
and intestinal epithelial cells have increased expression of
CD94/NKG2C and NKG2D ligands (MICA and HLA-E)
[24]. The interaction of NK receptors with their ligands
leads to the death of intestinal epithelial cells and releases
IFN-γ and cytolytic proteins (perforin, granzymes, etc.),
resulting in observable tissue damage. IL-15 has been shown
to upregulate both CD94/NKG2C and NKG2D NK receptors
in IELs of active patients, boosting their ability to lyse
enterocytes [15, 24].
1.2.3. Innate Immune Response. Some gluten peptides can
induce tissue damage by directly activating components of
innate immunity [25]. The peptide p31-43/49 has been
shown to activate the production of IL-15 and the NK-
receptor-mediated cytotoxicity by IELs, independent of TCR
specificity [26]. The presence of a receptor for p31-43/49 in
intestinal epithelial cells has not been found yet and, thus,
the molecular mechanism underlying the biological eﬀects
observed for this peptide remains unclear [15].
2. Influence of Dietary Factors on Immune
Development in a CD Context
Dietary factors aﬀecting disease risk in later life seem particu-
larly relevant at early stages when the immature neonate’s gut
is acquiring and shaping its own microbiota and undergoing
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major physiological and immunological developments up to
the point when the immune system acquires full competence
and tolerance to nonharmful antigens [27].
Infants’ first exposure to dietary gluten seems particularly
important in defining the risk of developing CD in predis-
posed subjects. The eﬀect of timing of gluten introduction on
CD was first reported at the end of the 1970s by pediatricians
in West Somerset, UK [28]. The authors noticed that the
incidence of CD declined from 1 : 1228 to 1 : 4168 following
the recommendations to avoid both the addition of cereals to
bottle feeds and the introduction of gluten before 4 months
of age. The role of age at the first gluten exposure in CD
onset was later studied by Norris et al. [29]. They carried
out a prospective observational study from 1994 to 2004
in 1560 children with an increased risk of CD or type I
diabetes, as carriers of either HLA-DR3 or DR4 alleles or as
having a first-degree relative with type I diabetes. In these
children they assessed the risk of CD autoimmunity (CDA)
defined as being positive for tissue transglutaminase (tTG)
autoantibody in two or more consecutive visits. The mean
followup was 4.8 years. Infants exposed to gluten in the
first three months of life have a 5-fold increased risk of
autoimmunity compared with infants first exposed at 4–
6 months (hazard ratio (HR) 5.17, 95% CI 1.44–18.57).
Infants introduced to gluten at 7 months or later also had an
increased risk of CDA compared with those exposed between
4 and 6 months (HR 1.87, 95% CI 0.97–3.00). This study
did not find any evidence for a protective eﬀect of prolonged
breastfeeding. The median duration of breastfeeding was 5
months both in CDA positive and in CDA negative children.
This analysis, however, was not restricted to HLA-DR3
children and possibly the protective eﬀect of breastfeeding
was evident only when children with genetic risk were
considered. The discrepancy between the results of this study
and others reporting the protective role of breastfeeding
might be explained by the diﬀerent methodologies between
retrospective and prospective studies. Another factor to
consider is the diﬀerent dietary practices in Europe and
the United States [29], since in Europe gluten tends to
be introduced as a replacement of breast milk at weaning
(e.g., the flour-based follow-up infant formula once used in
Sweden) whereas in the United States this does not seem to
be the case. Some explanations have been reported by Norris
et al. [29] for the increased risk of CDA when first gluten
exposure occurs in younger and older children instead of at
the age of 4–6months. On the one hand, in younger children,
early introduction of solid foods (i.e., before the intestinal
immune system reaches a certain level of maturation) may
lead to intolerance [30]. On the other hand, in children aged
7 months or older, the factor leading to the increased risk of
CDA might be the large amounts of gluten intake at the first
exposure [29].
A position paper by the ESPGHAN Committee on
Nutrition has outlined possible practical suggestions on the
introduction of complementary feeding to avoid both early
(<4 months) and late (≥7 months) introduction of gluten,
and to gradually introduce small amounts of gluten whilst
the infant is still breast-fed [31]. This change in the policy
of complementary feeding is aimed at modulating the pre-
disposition of chronic disorders later in life (particularly of
CD) and has already been adopted by countries like Australia
[32]. This is, however, still a matter of debate since exclusive
breastfeeding for around six months is considered a desirable
goal both by ESPGHAN [33] and the WHO, in order to
support healthy growth and development and reduce the
risk of infections. Furthermore, the evidence for beneficial
eﬀects of delaying the introduction of complementary foods
until 6 months is very limited, and diﬃcult to support in
the face of emerging evidence that it may be detrimental
[34]. As suggested by Agostoni and Shamir [31] perhaps
the 6-month theorem should be partly revised and small
amounts of solids, including gluten, be allowed in the 4
to 7-month temporary window to modulate the genetic
predisposition towards an autoimmune response, especially
in developed countries were the exposure to infectious
agents diﬀers from that in the developing countries and,
therefore, the risk of infections. However, the time of first
exposure to potentially allergenic foods in infants diﬀers
significantly between countries, and they are introduced
much earlier than recommended in some countries [35].
Moreover, formula-fed infants receive potentially allergenic
foods earlier than breast-fed infants [35].
The protective role of breastfeeding against CD onset has
been reviewed and analyzed in a meta-analysis of observa-
tional retrospective studies published in May 2004, which
concluded that increased duration of breastfeeding is asso-
ciated with a reduced risk of CD [36]. Five of the six case-
control studies satisfying the inclusion criteria of method-
ological quality, found that children with CD had been
breastfed for a significantly shorter period compared to
controls. Age at the time of risk evaluation was variable
among participants and among studies, ranging from less
than 2 years to a median of 7.9 years. Also, the meta-
analysis of four of these studies led to the conclusion that the
risk of developing CD was significantly reduced in children
who were breastfed at the time of gluten introduction (OR
0.48, 95% CI 0.40 to 0.59). However, the reviewed studies
do not clarify whether breastfeeding only delays the onset
of symptoms or provides permanent protection against the
disease. Furthermore, the results of the meta-analysis are
subject to limitations such as “recall bias” whereby the
duration of breastfeeding and the age of first gluten exposure
may be mistaken, or another bias might be derived from
suboptimal adjustment for potential confounding factors
across children who were breastfed and those who were not.
For instance, only one of the studies controlled the HLA
genotype and this was the only study that did not find a
relationship between breastfeeding and protection against
CD; however, since this was a very small study registering
only eight cases of children with CD, a type II error was likely
to have occurred.
The study by Ivarsson et al. [37], included in the meta-
analysis, is a population-based incident case-referent study
of 627 cases with confirmed CD (reported to a CD register
between November 1992 and April 1995) and 1254 referents
assessing patterns of complementary food introduction to
infants. The study revealed that the risk of CD was reduced
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in Swedish children aged <2 years if they were still being
breast-fed when dietary gluten was introduced (adjusted OR:
0.59; 95% CI: 0.42–0.83) and the risk increased when the
gluten was introduced in the diet in large amounts (OR:
1.5; 95% CI: 1.1–2.1). In this study the eﬀect of age at
the time of gluten introduction was not conclusive. It is
biologically likely that the presence of breast milk at the
time gluten is introduced increases the chance of developing
oral tolerance for the antigens of importance. It is unclear
whether this possibility is only eﬀective during a certain
period in infancy. In the aforementioned study, the exposure
risk factors explored were of no or only minor importance
in children older than 2 years. Therefore, it is also important
to pursue further whether favorable infant dietary patterns
postpone CD onset or in fact reduce the overall lifetime risk
of the disease [37].
Previous to this analysis of risk factors, the authors had
documented an epidemic of symptomatic CD between 1984
and 1996 in Swedish children under 2 years of age, partially
explained by changes in infant feeding [38]. The increased
incidence was preceded by an increase in the amount
of gluten consumed and by delayed exposure to dietary
gluten, which might have resulted in a higher proportion of
children being introduced to large amounts of gluten after
breastfeeding was withheld. Recently, a Swedish study of the
prevalence in children born in 1993, during the epidemic,
and under these unfavorable dietary practices, revealed that
the prevalence of CD at 12 years of age was as high as 3%,
3-fold higher than the commonly reported prevalence of 1%
[39].
Other recent studies have pointed to the role of breast-
feeding in delaying CD in infancy. D’Amico et al. [40]
showed that children with CD who had been exclusively
breastfed had a delayed onset and less severe disease symp-
toms than those who had not been exclusively breastfed [40].
Medical records of 89 infants (7–14 months of age) diag-
nosed with classic CD at the University Children’s Hospital
in Belgrade, from 2000 to 2008, were retrospectively analyzed
to determine the duration of breastfeeding and timing of
gluten introduction [41]. Breastfeeding, although generally
short, significantly reduced the risk of CD onset in the first
year of life (OR 0.655; 95% CI 0.48 to 0.89); moreover, the
duration of breastfeeding was the most significant predictor
of developing CD (B = 0.49; 95% CI 0.13 to 0.77). One-
fourth of the infants were being breastfed at the time of
gluten introduction, and they developed the disease later
than the infants who were not being breastfed at the time
of gluten introduction. This finding supports the protective
eﬀect of consuming human milk while introducing other
food antigens [41]. However, this study also poses the
question of whether the action of breastfeeding might not
indirectly delay the onset, the symptoms, and the diagnosis
due to a delay in gluten exposure in breast-fed infants.
In spite of all the evidence reported, it remains unclear
whether those children breast-fed during the introduction
of gluten are more likely to develop an extraintestinal
(“atypical”) CD [42]. A series of 162 celiac children registered
by the University of Chicago, revealed that children breast-
fed at the time of gluten introduction were just as likely
to develop intestinal as extraintestinal symptoms, whereas
children who were not breastfed when weaned with gluten
had amuch higher chance of developing intestinal symptoms
[43].
Given the gaps in knowledge and the limitations of
the studies described above, it seems clear that long-term
prospective cohort studies are required to investigate further
the relationship between breastfeeding and CD.
The following hypotheses have been formulated to
understand the protective role breastfeeding plays in CD
onset.
(a) Breastfeeding might aﬀect tolerance induction in
infants because of both the possible transfer of small
amounts of gluten and gluten-specific IgA antibodies
through breast milk and the presence of factors
in breast milk that aﬀect immune system matu-
ration and responses [44]. Human milk provides
many bioactive factors, including antimicrobial and
anti-inflammatory agents, enzymes, hormones, and
growth factors, many of which are involved in gut
maturation and development of the infant’s innate
and acquired immunity [45, 46]. A particular feature
of the neonatal immune system is the presence of a
wide pool of naı¨ve T cells waiting to participate in
primary immune responses. Intestinal antigen expo-
sure during neonatal life influences the T cell receptor
(TcR) repertoire of these developing immature T cells
[47]. In our recent PROFICEL study the combined
eﬀect of HLA-DQ genotype and milk-feeding prac-
tices at 4 months of age on peripheral lymphocyte
subsets was studied in a group of infants with at
least one first-degree relative suﬀering from CD.
Our analysis revealed an independent eﬀect of milk-
feeding practices on specific T cell subsets. The results
showing a higher percentage of T CD4+CD25+ cells
and lower T CD4+CD38+ counts in breast-fed than
in formula-fed infants, suggest that breast-fed infants
could have a more mature immune system than
formula-fed infants [48]. Further research is now
underway to ascertain whether the lymphocyte subset
profile of breast-fed infants is associated with a better
response to gliadin after gluten introduction.
(b) Children that are breastfed when gluten is introduced
during weaning, receive lower amounts of gluten,
even on a protein/kg body weight basis [42].
(c) As suggested from studies showing a reduced risk of
childhood type I diabetes with breastfeeding and late
introduction of cow’s milk, it seems plausible that in
addition to the immunologically active components
in breast milk, avoidance of the early introduction of
cow’s milk protein contributes to the protective eﬀect
of breastfeeding [31]. This might also be the case for
the role of breastfeeding in CD prevention.
(d) Other reasons that could explain a protective eﬀect
of breastfeeding against CD development could be
related to the role human milk plays in defining
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microbiota composition [49] and in the incidence of
infections, which is explained in the next section.
3. Intestinal Microbiota and CD
The composition of the intestinal microbiota has also been
related to CD recently. The first associations were established
in CD patients, untreated and treated with a gluten-free
diet [50–52]. The intestinal dysbiosis of CD patients was
characterized by increases in numbers or proportions of
Bacteroides spp. and reductions in those of Bifidobacterium
spp. and B. longum, which were not completely normal-
ized after patient adherence to a GFD [50–52]. E. coli
and Staphylococcus numbers were also higher in feces and
biopsies of untreated CD patients than in those of controls,
but the diﬀerences were normalized after gluten withdrawal
[51]. The analyses of the prevalence of bacterial species
associated with duodenal biopsies also revealed a reduction
in Bacteroides species diversity in patients, untreated and
treated with the GFD, in comparison with controls [53]. In
addition, E. coli clones isolated from untreated and treated
CD patients carried a higher number of virulence genes than
those from healthy children. These findings indicated that
intestinal dysbiosis is associated with CD and that some of
the alterations are not only secondary to the inflammatory
milieu of the active phase of this disorder, but might play a
primary role together with genetics and gluten intake in this
disorder.
Further studies are ongoing to establish the possible
eﬀects of milk-feeding patterns and HLA-DQ genotype on
the microbiota in early life, and the possible influence
on later development of CD [54, 55]. In this context, a
prospective study including 164 healthy newborns, with at
least one first-degree relative with CD, indicated that both
the milk-feeding type and the HLA-DQ genotype play a
role in establishing infants’ gut microbiota [55]. Reduced
numbers of Bifidobacterium spp. were found in infants
with an increased risk of developing CD in the whole
population and in breast- and formula-fed infants, although
breastfeeding favored gut colonization by species of this
genus. The findings, therefore, suggest that Bifidobacterium
spp. and B. longum numbers can be influenced by both HLA-
DQ genotype and milk-feeding type. Increased numbers of
Staphylococcus spp. were associated with increased genetic
risk of developing CD in the whole population and in
both subgroups of breast- and formula-fed infant, and the
colonization of this bacterial group was not significantly
favored by a specific type of milk-feeding, suggesting that
the HLA-DQ genotype plays a more prominent role in the
colonization of this bacterial group. In contrast, increased
numbers of the B. fragilis group were found in infants
with high genetic CD risk; however, this association was
only confirmed in the subgroup of formula-fed babies but
not in those breast-fed, indicating that the type of milk
feeding is the main factor influencing the colonization of
this bacterial group [55]. A study into the prevalence of
Bacteroides spp. in a subgroup of this cohort of infants also
showed that B. vulgatus prevalence was higher in infants
at high genetic risk of developing CD, while B. uniformis
prevalence was increased in infants at low genetic CD risk
and in breast-fed infants [54]. Overall, breastfeeding seems
to reduce the microbial diﬀerences related to the HLA-DQ
genotype, which could partly explain the protective eﬀect of
humanmilk reported in some previous observational studies
[36, 37]. The followup of this cohort of infants is underway
to reveal additional evidence of the role played by early
intestinal microbial colonization of the infant’s gut in CD
development.
Breast milk contains human oligosaccharides (HMOs),
which seem to contribute to shaping the composition of the
microbiota and selectively stimulate the growth of specific
bacterial groups, such as bifidobacteria, in the infant’s gut
[56]. In breast-fed infants Bifidobacterium spp. predominate,
representing up to 90% of the total fecal microbiota, whereas
in formula-fed infants the microbiota is more heteroge-
neous and integrated by members of more diverse gen-
era (Streptococcus, Bacteroides, Clostridium, Bifidobacterium,
etc.) [57, 58]. In recent years, the presence of commensal
bacteria in breast-milk of healthy women and their possible
transmission to the newborn has also been proposed [59,
60]. The main bacterial genera detected in breast-milk are
Streptococcus and Staphylococcus, representing 36–65% and
29–50% of the total bacteria, respectively, while the genus
Bifidobacterium only represents 3-4% [61]. However, Bifi-
dobacterium spp. becomes predominant in the gut of breast-
fed infants, probably due to their better metabolic adaptation
to utilizing HMOs as revealed by genome sequencing [62].
The transfer of bifidobacteria from the mother’s milk to
the infant has been demonstrated by comparing bacterial
strains present in mother-infant pair samples [63]. However,
the mechanism involved in the colonization on human
milk remains unclear. Martı´n et al. [64] observed diﬀerent
lactic acid bacteria in breast skin and milk, suggesting that
these bacteria had a diﬀerent origin and proposing an
endogenous route for breast milk colonization. Meanwhile,
in vitro studies reported that dendritic cells (DCs) of the
lamina propria could penetrate the intestinal epithelium and
capture viable bacteria from the lumen, via the opening of
the tight junctions between epithelial cells [65]. Commensal
bacteria from the mother’s gut could use this mechanism
to migrate from the intestinal mucosa and colonize the
mammary gland. Nevertheless, some animal experiments
questioned the complete molecular mechanism involved in
this colonization, showing that commensal bacteria in DCs
were eﬃciently killed by macrophages and only pathogens
were able to survive in high numbers and during prolonged
periods of time [66].
The early colonization of the intestine by the microbiota
seems to exert a strong influence on the development of
mucosal and systemic immunity, as evidenced by studies
conducted with germ-free and colonized mice. In germ-free
mice, the serum immunoglobulin levels were reduced and
spleens were smaller and the gut-associated lymphoid tissue
was immature, with a low content of lamina propria T cells,
immunoglobulin (Ig) A producing B cells and intraepithelial
T cells; however, these deficiencies were restored after
colonization with commensal bacteria [67]. Human studies
have also reported that the bacteria colonizing the newborn
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intestine modifies production of salivary secretory IgA,
numbers of circulating IgA and IgM antibody-producing
cells as well as the expression of innate immune receptors
(e.g., Toll-like receptor) in peripheral blood monocytes [68,
69]. A previous prospective observational study also reports
that changes in microbiota composition, characterized by
a reduced ratio of Bifidobacterium to Clostridium counts,
early in life precede the development of atopic dermatitis
[70], suggesting that the microbiota plays a role in the risk
of developing immune-mediated diseases. In this context,
other authors [59] also described diﬀerences in breast-
milk microbiota, characterized by decreased concentrations
of Bifidobacterium spp. in the milk of allergic mothers
compared to healthy mothers, as well as the impact of these
diﬀerences on the infant’s fecal levels of Bifidobacterium spp.
4. Infections and CD
Infectious agents are considered as possible environmental
factors triggering autoimmune diseases. In CD, exposure to
infectious agents (viral or bacterial) has also been suggested
as a factor causing tissue damage and inflammation, which
could eventually contribute to reduced gluten tolerance [71].
Infections can influence the host’s immune tolerance by
diﬀerent mechanisms. These include polyclonal lymphocyte
activation, increased immunogenicity of organ autoantigens
secondary to infection-mediated inflammation, or antigen
mimicry molecular mechanisms [72]. In the last case, the
autoimmune response is caused by cross-reactivity between
host (human) epitopes and immunologically similar epi-
topes in the infectious organism. The list of such homologies
in the bioinformatics-based search is long and can be
relevant in some cases. Nonetheless, such homologies do
not demonstrate definite evidence for a possible role of the
shared antigenic determinant between the infectious agent
and the autoantigen [72].
Several studies have described a possible link between CD
onset in susceptible patients with diverse infectious agents,
and these associations are even traced back to the perinatal
period. Several hypotheses about the possible pathogenic
mechanisms behind these associations have been discussed
in recent years, including antigen mimicry and increased
immune activation secondary to infection-mediated inflam-
mation, for example by induction of TNF (tumor necrosis
factor)-α, IFN-γ and IL-15 [73].
In Sweden, a study of 3,392 infants born between 1987–
1997, who ultimately developed CD, compared various
perinatal data to those of healthy infants and reported that
the main risk factor for developing CD was exposure to
neonatal infections (OR 1.52; CI 1.19–1.95) [74].
Another study has attempted to establish an association
between CD and infections by assessing the serum pathogen-
specific antibodies in CD patients compared to the general
population [75]. This study examined the association of
CD with five major infectious agents, including Toxoplasma
gondii, rubella virus, cytomegalovirus (CMV), Treponema
pallidum and Epstein-Barr virus (EBV). The serological
results demonstrated a lower prevalence of IgG antibodies
in CD patients compared to healthy subjects, suggesting a
possible protective role of infections (clinical or subclinical)
by EBV, CMV, and rubella on CD development.
One of the first infectious agents associated with CD
was the adenovirus type 12 (Ad12). It was proposed that
CD could be triggered by the Ad12 infection through
mimicry of a peptide within the alpha-gliadin by the Elb
protein of this adenovirus 12 [76], but further studies did
not support this hypothesis. In one of them, five murine
monoclonal antibodies against a synthetic dodecapeptide of
α-gliadin were tested against whole-wheat gliadin and its
subfractions and the prolamins of rye, barley, oats, maize,
millet, rice, and sorghum. Four of the antibodies cross
reacted with one or more of the celiac nontoxic cereals, and
the other did not recognize Frazer’s fraction III, a peptic-
tryptic digest of wheat-gluten which is known to be toxic
[77]. Other studies based on the detection of DNA coding
for the E1B-58 kDa protein of this adenovirus on intestinal
mucosal biopsies refuted the correlation between CD and
active Ad12 infection, although remote infection prior to
CD onset could not be excluded [78, 79]. Studies based on
detection of antibodies against the virus in serum of CD
patients in comparison with controls are also contradictory
regarding the association of infection with CD. In a study
in favor of this hypothesis, involving 44 children with CD
and 60 matched-controls, CD children had significantly
higher IgG antibody levels against the Ad12 E1b peptide
than the controls [80]. In contrast, another study, including
23 CD patients and 10 control subjects, did not report
increased presence of specific antibodies against the E1b-58-
kDa protein in serum of CD patients [81].
Another infectious agent epidemiologically associated
with CD onset is the hepatitis C virus (HCV). The prevalence
of CD in patients with chronic liver disease is 15 times
higher than that in the general population [82], and CD is
also present in about 5% of the patients with autoimmune
hepatic disease [83]. Although HCV has been identified to
cause secondary autoimmune processes in other parts of the
body, several studies have failed to find increased prevalence
of CD in patients with HCV infection [84] and concluded
that the association between HCV and CD can be causal or a
coincidental finding [85].
Gastrointestinal pathogens like rotavirus have also been
linked to CD [86]. The association is based on a prospective
study of a cohort of 1,931 children carrying CD HLA
risk alleles. This study reported that high frequency of
rotavirus infections, estimated by measuring the increase in
rotavirus antibodies, may raise the risk of CD autoimmunity,
defined as positivity at two or more clinic visits for tissue
transglutaminase (tTG) autoantibodies. In addition, there
are also studies in which the disease has been associated
with Campylobacter jejuni, [87] and Giardia lamblia [88].
Although some of these reports are case studies based on
a single patient, they suggest that gastrointestinal infections
may trigger or facilitate the onset of clinical CD by increasing
intestinal permeability [3] or by amplifying the immune
response to gliadin.
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5. Involvement of Genetic Factors in CD and
Autoimmune Diseases Influencing Immune
SystemDevelopment
As we described previously, the HLA-DQ genes contribute
to the 40% of the sibling familial risk of CD and non-
HLA linked genes are likely to be the stronger determinants
of CD susceptibility [89]. Two complementary approaches
have been used to target the genes that account for the
remaining 60% genetic linkage and association studies [5].
The genomewide association studies (GWAS) identified a
large number of genes involved in CD and other autoim-
mune diseases outside the HLA region. Some of these
genes are IL-2 and IL-21 genes in 4q27 region [3]. In
addition, six previously unknown risk regions harboring
genes controlling immune responses were identified (CCR3,
IL12A, IL18RAP, RGS1, SH2B3, and TAGAP) [90]. Dubois
et al. [91] found 13 new genetic risk regions. They described
four specific immunological pathways that are relevant to CD
pathogenesis, in which genes included in the 13 new risk
regions participate. These pathways are involved in (1) T-
cell development in thymus, comprising THEMIS, RUNX3,
and TNFRSF14 genes; (2) innate immune detection of viral
RNA, including TLR8 gene; (3) T- and B-cell costimula-
tion, including CTLA-4, ICOS-CD28, TNFRSF14, CD80,
ICOSLG, TNFRSF9, TNFSF4 genes; and (4) production
of cytokines, chemokines and their receptors, including
TNFSF18 and CCR4 genes.
CD has been associated with autoimmune diseases,
particularly with type I diabetes, rheumatoid arthritis, and
autoimmune thyroiditis [4, 5]. CD, type I diabetes (T1D),
and rheumatoid arthritis (RA) share the HLA region, and
other non-HLA regions, including IL2-IL21, SH2B3, and
TAGAP regions [92, 93]. CD and T1D have both shown
rising incidence in recent years [92], and it has been sug-
gested that gluten consumption, and gut permeability and
inflammation are also factors involved in the development
of T1D [94]. T-cell infiltration in the target organs, the
development of disease-specific autoantibodies, and the role
of enzymes involved in posttranslational modifications in
the pathogenesis of the diseases are common features in
CD and RA although they are distinct in their phenotype
[93]. Further studies into the interactions between genetic
and environmental factors are necessary to establish the
biological mechanisms underlying the development of these
diseases and for the design of possible immunomodulatory
strategies to interfering some of the common pathologic
mechanisms for disease prevention.
6. Possible Induction of
Acquired Gluten Tolerance
Administration of antigens by the oral route induces
hyporesponsiveness to subsequent challenge with the antigen
given in an immunogenic form, usually by a parenteral
route, a phenomenon termed oral tolerance [95]. Oral
tolerance, however, usually aﬀects the response of the local
immune system in the intestinal mucosa, thus, preventing
hypersensitivity reactions to food proteins that could lead
to disorders such as CD or food allergies [96]. Similarly,
immunological tolerance prevents the aberrant immune
responses to commensal bacteria in the gut [95]. However,
the acquisition of oral tolerance is a complex process and is
far from being fully elucidated.
Because CD activity is strongly correlated to the presence
and dosage of gluten, the induction of gluten-specific oral
tolerance is an attractive therapeutic approach. In this
line, one population study is currently being carried out
to seek new strategies for CD prevention during early
of life. PREVENT CD is a project funded under the
European Union’s FP6, studying the possible induction
of gluten tolerance in genetically predisposed children.
This is a prospective, randomized, blind dietary inter-
vention in young children from high-risk families for
CD (http://www.preventceliacdisease.com/). The rationale is
that introducing small amounts of gluten and gradually
increasing the amount during a certain timeframe in the
infant’s development, preferably while they are still being
breastfed, will induce oral tolerance to gluten. A total of
1000 children with at least a first-degree relative suﬀering
from CD will participate in this intervention study and
followed up for 3 years. From the 4th to 6th months of life
they will receive a small amount of gluten, which will be
gradually increased during months 6 to 9, and followed by
free intake thereafter. The objective of this intervention is
to decrease the incidence of CD in the group receiving the
gluten supplement compared to the group receiving placebo.
Studies published in the 1980–1990s led to the idea
that the mechanisms responsible for oral tolerance depend
on the feeding pattern, which can induce tolerance by
either clonal anergy (or deletion) of specific T cells or
by the induction of regulatory T (Treg) cell activity [97].
More recent knowledge has pointed out antigen presenting
cells (APCs) as fundamental players directing tolerance or
immunity towards specific antigens.
Generation of immunological tolerance has been
attempted through ingested or inhaled soluble proteins
via the oral and nasal routes [98]. An attempt was made
to induce gliadin tolerance in HLA-DQ8 transgenic mice
immunized by intra foot pad injections of gliadin in
Freund’s adjuvant, after soluble gliadin had previously
been instilled into their nostrils following a tolerization
protocol. A decrease in systemic T cell responses to
the recombinant α-gliadin was found, as reflected by a
lymphocyte proliferation assay. While the immunization
protocol induced transcription of both Th1 and Th2
cytokines, the tolerization protocol only significantly
down-regulated IFN-γ mRNA expression [99]. This
finding highlights the potential use of this strategy for the
immunomodulation of this disease. However, the presence
of gliadin-specific T cell clones in transgenic mice models
is not suﬃcient to develop enteropathy and, therefore, the
down-regulation of these clones might not be suﬃcient
alone to control the disease, necessitating the control of
other pathogenic pathways involved in CD.
DCs play a central role in intestinal immune responses
to dietary proteins and commensal microbiota. Current
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evidence suggests that tolerance requires migration of DCs
that have taken up antigens in the mucosal lamina propria
to the mesenteric lymph nodes (MLNs) [100]. On the
other hand, the production of TGF-β and retinoic acid
(RA) by DCs drives the development of Treg cells. IL-
15 reduces the ability of DCs to induce the generation
of Treg cells and, unexpectedly, RA synergizes with IL-
15 in reducing the number of Treg cells [101]. A double
transgenic murine model partially reproducing human CD
was used to demonstrate that RA synergizes with IL-15 in
promoting gluten tolerance breakdown by inducing DC-
mediated production of proinflammatory cytokines (IL-12
and IL-23) and a Th1 response to gluten [101]. Therefore, RA
is not only a mediator of tolerance (as previously thought),
but in the presence of other cytokines it may activate DCs
towards a proinflammatory phenotype and induce specific
proinflammatory Th1 responses. Therefore, future immune
therapies based on RA, aiming to restore oral tolerance,
should be employed with caution because the presence of IL-
15 (and/or other proinflammatory cytokines) may also have
undesirable eﬀects.
With respect to restoring immune tolerance, it is worth
mentioning the development of a peptide-based therapeutic
vaccine, which has induced immune tolerance in rodent
models of HLA-DQ2-restricted T-cell immunity to gluten
[102]. The safety of this preparation (a combination of toxic
peptides termed Nexvax2; Nexpep, Ivanhoe, Vic, Australia),
aimed at inducing desensitization as traditional vaccines do,
is currently under investigation in patients with treated CD.
Active delivery of recombinant autoantigens or allergens
at the intestinal mucosa by genetically modified Lactococcus
lactis has also been proposed as a novel therapeutic approach
for tolerance induction. L. lactis was genetically engi-
neered to secrete a deamidated DQ8-specific gliadin epitope
(DQ8d), which is immunodominant for DQ8-mediated T-
cell responses (LL-eDQ8d). Its oral supplementation toNOD
AB◦ DQ8 transgenic mice (using the NOD background,
which contributes to autoimmunity and pathogenesis, in
combination with expression of a human DQ8 MHC class
II transgene, which contributes to sensitivity to gliadin)
was studied [103]. This treatment resulted in an Ag-specific
decrease of the proliferative capacity of inguinal lymph node
cells and lamina propria cells. Production of IL-10 and
TGF-β and a significant induction of Foxp3+ regulatory T
cells were associated with the eDQ8d-specific suppression
induced by LL-eDQ8d [103]. These data provide support
for the development of eﬀective therapeutic approaches
for gluten-sensitive disorders using orally administered Ag-
secreting L. lactis.
The studies showing that intestinal dysbiosis is associated
with CD and that there are diﬀerences in the intestinal
colonization pattern of infants with diﬀerent genetic risk of
developing CD and under diﬀerent types of milk-feeding,
would suggest the potential use of interventions with pro-
biotics in the gut ecosystem to promoting the development
or increasing gluten tolerance. So far, B. longum CECT 7347
(IATA-ES1) and B. bifidum CECT 7365 (IATA-ES2) have
been shown to reduce inflammatory cytokine production
(IFN-γ and TNF-α) induced by the altered microbiota of
CD patients, and to increase IL-10 production by peripheral
blood mononuclear cells in vitro [104]. These bifidobacterial
strains also provide protection against inflammation and
mucosal damage triggered by gliadin peptides, combined or
not with IFN-γ, in Caco-2 cultures [105] and in intestinal
loops of germ-free rats [105, 106]. In intestinal loops, B.
bifidum CECT 7365 increased the number of goblet cells
in the small intestine, which were reduced by the presence
of gliadin, IFN-γ and enterobacteria, and upregulated ZO-1
expression, which was downregulated by CD triggers (gliadin
peptides and IFN-γ) [106]. B. bifidum CECT 7365 also
increased the production of inhibitors of metalloproteinases
(TIMP-1), which could contribute to gut mucosal protection
[106]. In an animal model of this enteropathy, induced by
oral administration of gliadin to neonatal rats sensitized with
IFN-γ, administration of B. longum CECT 7347 attenuated
inflammatory cytokine (TNF-α) production and induced IL-
10 production in the small intestine, and also attenuated
the CD4+ T-cell mediated immune response in peripheral
blood. In contrast, Bifidobacterium lactis NCCC2818 and
several strains of Lactobacillus spp. (L. plantarum ITM21B,
L. paracasei IMPC2.1, L. fermentum DRL38, and L. casei
ATCC 9595) exerted inductive rather than suppressive eﬀects
on both the innate and adaptive immunity in cell cultures
in vitro and in vivo in DQ8 transgenic mice administered
gliadin intragastrically and cholera toxin as adjuvant [107].
The eﬀects of the strains on immature bone marrow-
derived DCs, extracted from these transgenic mice, were
analyzed in vitro. Results showed that all strains increased
CD86 expression, indicative of DC maturation, none of
the strains induced IL-10 or IL-12 production, while L.
paracasei IMPC2.1 and L. fermentumDRL38 increased TNF-
α expression. Moreover, in vivo administration of these
strains to the same DQ8 transgenic mouse model enhanced
the antigen-specific TNF-α secretion. In the same DQ8
mouse model, in vivo administration of L. casei ATCC 9595
increased the gliadin-specific response mediated by CD4(+)
T cells, increasing the gliadin-specific IFN-γ expression and
proinflammatory polarization of the cytokine milieu in the
small intestinal mucosa. In the light of these results, it
was suggested that L. casei ATCC 9595 could be used as
vaccine adjuvant to enhance both mucosal and systemic T
cell-mediated responses to gluten [108]. Subsequent studies
were conducted in the same DQ8 transgenic mice, which
were intragastrically administered gliadin and cholera toxin
as an adjuvant and were also given indomethacin orally to
induce the tissue lesions. Results showed that L. casei ATCC
9595 restored intestinal damage and TNF-α production,
but positive eﬀects on gliadin-specific production of IFN-
γ, IL-10, and IL-4 were not detected [109]. However, the
animal models and experimental conditions used were not
comparable, thus definitive conclusions cannot be drawn
about the diﬀerential eﬀects of diﬀerent bacterial strains.
Moreover, further animal studies focusing on CD prevention
would be required to sustain the notion that specific
components of the gut microbiota can contribute to the
development of gluten tolerance in early life.
In addition, human studies would be essential to defini-
tively conclude that specific bacteria play a protective role
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in CD patients, or susceptible individuals, by modulating
immune responses and inducing or increasing tolerance to
gluten.
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